Evidence map›Paper›PMID 37858180›Full record

ArticleOrphanet journal of rare diseases2023

Does the registry speak your language? A case study of the Global Angelman Syndrome Registry.

Megan Tones, Nikolajs Zeps, Yvette Wyborn, Adam Smith, Roberto A Barrero, Helen Heussler, Meagan Cross, James McGree, Matthew Bellgard

Registry-linked trialOpen access · goldAbstract readLetter
In one paragraph

Article in Orphanet journal of rare diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05293184 (The Global Angelman Syndrome Registry), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05293184 recruitingnot on this map

The Global Angelman Syndrome Registry

Typeobservational_patient_registrySponsorFoundation for Angelman Syndrome Therapeutics, AustraliaRan2016 to 2099Enrolled5,000ConditionsAngelman SyndromeArmsObservational study only
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Megan TonesOffice of eResearch, Queensland University of Technology, Brisbane, QLD, 4000, Australia. m.tones@qut.edu.au.ORCID http://orcid.org/0000-0003-0482-7489
Nikolajs ZepsOffice of eResearch, Queensland University of Technology, Brisbane, QLD, 4000, Australia.
Yvette WybornOffice of eResearch, Queensland University of Technology, Brisbane, QLD, 4000, Australia.
Adam SmithOffice of eResearch, Queensland University of Technology, Brisbane, QLD, 4000, Australia.
Roberto A BarreroOffice of eResearch, Queensland University of Technology, Brisbane, QLD, 4000, Australia.
Helen HeusslerCentre for Clinical Trials in Rare Neurodevelopmental Disorders, Child Development Program, Children's Health Queensland, Child Health Research Centre University of Queensland, Brisbane, QLD, 4101, Australia.
Meagan CrossFoundation for Angelman Syndrome Therapeutics Australia, Salisbury, QLD, 4107, Australia.
James McGreeSchool of Mathematical Sciences, Queensland University of Technology, Brisbane, Australia.
Matthew BellgardOffice of eResearch, Queensland University of Technology, Brisbane, QLD, 4000, Australia. m.bellgard@uel.co.uk.
Queensland University of Technology · AUThe University of Queensland · AUUniversity of East London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Global disease registries are critical to capturing common patient related information on rare illnesses, allowing patients and their families to provide information about their condition in a safe, accessible, and engaging manner that enables researchers to undertake critical research aimed at improving outcomes. Typically, English is the default language of choice for these global digital health platforms. Unfortunately, language barriers can significantly inhibit participation from non-English speaking participants. In addition, there is potential for compromises in data quality and completeness. In contrast, multinational commercial entities provide access to their websites in the local language of the country they are operating in, and often provide multiple options reflecting ethnic diversity. This paper presents a case study of how the Global Angelman Syndrome Registry (GASR) has used a novel approach to enable multiple language translations for its website. Using a "semi-automated language translation" approach, the GASR, which was originally launched in English in September 2016, is now available in several other languages. In 2020, the GASR adopted a novel approach using crowd-sourcing and machine translation tools leading to the availability of the GASR in Spanish, Traditional Chinese, Italian, and Hindi. As a result, enrolments increased by 124% percent for Spain, 67% percent for Latin America, 46% percent for Asia, 24% for Italy, and 43% for India. We describe our approach here, which we believe presents an opportunity for cost-effective and timely translations responsive to changes to the registry and helps build and maintain engagement with global disease communities.

Indexed as

Angelman SyndromeAsiaGlobal HealthHumansLanguageRegistriesDisease RegistryEquity diversity and inclusionLanguage translationPatient reported outcomes

Identifiers

PMID37858180
PMCPMC10588126
OpenAlexW4387773601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.